Study of Etoposide in Breast Cancer Patients

Completed

Conditions studied: Breast Cancer

In brief

This study will examine how the body handles etoposide, a drug used to treat breast cancer. The knowledge gained may lead to more effective use of the drug with fewer side effects in the future. Breast cancer patients who are receiving etoposide as part of their treatment may participate in this study. Patients will have 18 blood samples (about a teaspoon or less each) drawn over a 72-hour period during and after their infusion of etoposide. The initial blood samples cannot be taken from the same intravenous line (small tube placed in a vein) used to deliver the etoposide, so a second line may have to be placed temporarily to obtain these samples.

Key facts

Study ID

NCT00026949

Run by

National Cancer Institute (NCI)

People needed

33

Starts

1999-08-01

Expected to finish

2004-08-01

Last updated by the study team

2008-03-04

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than or equal to 18 years.
• Patients with breast cancer who are entered on existing Medicine Branch protocols that include high-dose etoposide.
• Must be able to provide informed consent.

Where it is running

• National Cancer Institute (NCI) — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.